Basis of Presentation (Tables)

6 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Adoption of New Revenue Recognition Standard Revenue Impacted Previously Reported

Adoption of new revenue recognition standard impacted the Company’s previously reported results as follows:

	Three months ended									Six months ended
	December 31, 2017									December 31, 2017
	As Previously Reported			ASC606 Adjustments			As Restated			As Previously Reported			ASC606 Adjustments			As Restated
Consolidated Statements of Operations:
Total Revenue	$	192.7		$	(4.8	)	$	187.9		$	380.6		$	(13.9	)	$	366.7
Selling, general and administrative expense		115.2			(7.8	)		107.4			230.4			(15.8	)		214.6
Income tax provision		(26.2	)		0.9			(25.3	)		(21.4	)		0.6			(20.8	)
Net Income attributable to Myriad Genetics, Inc. stockholders		28.8			2.1			30.9			108.4			1.3			109.7
Earnings per share:
Basic	$	0.42		$	0.03		$	0.45		$	1.57		$	0.02		$	1.59
Diluted	$	0.40		$	0.03		$	0.43		$	1.52		$	0.02		$	1.54
Consolidated Statements of Cash Flows:
Net Income attributable to Myriad Genetics, Inc. stockholders											108.4			1.3		$	109.7
Trade Accounts Receivable											(32.5	)		(19.5	)		(13.0	)

	June 30, 2018
	As Previously Reported		ASC606 Adjustments		As Restated
Consolidated Balance Sheet:
Trade accounts receivable	$	98.3	$	1.2	$	99.5
Retained Earnings		52.9		1.2		54.1